Bronchiectasis in Europe: data on disease characteristics from the European Bronchiectasis registry (EMBARC)-Reference-Cited by-同舟云学术

Bronchiectasis in Europe: data on disease characteristics from the European Bronchiectasis registry (EMBARC)

Published:2023-07 Issue:7 Volume:11 Page:637-649
ISSN:2213-2600
Container-title:The Lancet Respiratory Medicine
language:en
Short-container-title:The Lancet Respiratory Medicine

Author:

Chalmers James D,Polverino Eva,Crichton Megan L,Ringshausen Felix C,De Soyza Anthony,Vendrell Montserrat,Burgel Pierre Régis,Haworth Charles S,Loebinger Michael R,Dimakou Katerina,Murris Marlene,Wilson Robert,Hill Adam T,Menendez Rosario,Torres Antoni,Welte Tobias,Blasi Francesco,Altenburg Josje,Shteinberg Michal,Boersma Wim,Elborn J Stuart,Goeminne Pieter C,Aliberti Stefano

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference46 articles.

1. The EMBARC European bronchiectasis registry: protocol for an international observational study;Chalmers;ERS Open Res,2016

2. Economic burden of bronchiectasis in Germany;Diel;Eur Respir J,2019

3. Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations;Aliberti;Lancet Respir Med,2022

4. Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research;Hill;Eur Respir J,2017

5. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study;Quint;Eur Respir J,2016

Cited by 91 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New-onset obstructive airway disease following COVID-19: a multicenter retrospective cohort study;BMC Medicine;2024-09-04

2. COVID-19 in patients with airways disease: COPD, asthma and bronchiectasis;COVID-19: An Update;2024-09-01

3. Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: results of PROMIS-I and PROMIS-II, two randomised, double-blind, placebo-controlled phase 3 trials assessing safety and efficacy over 12 months;The Lancet Respiratory Medicine;2024-09

4. Real-world treatment patterns, health care resource utilization, and costs in a US Medicare population with bronchiectasis;Journal of Managed Care & Specialty Pharmacy;2024-09

5. Clinical Impacts of Pseudomonas aeruginosa Isolation in Patients with Bronchiectasis: Findings from KMBARC Registry;Journal of Clinical Medicine;2024-08-24